Tocagen Names Regulatory VP

San Diego-based cancer therapeutics developer Tocagen said this morning that it has named John Wood as its new Vice President of Regulatory Affairs and Quality Assurance. Wood was most recently at Arena Pharmaceuticals, and previously also served at Amylin Pharmaceuticals and IDEC Pharmaceuticals, along with Quintiles Consulting and Gensia, Inc. Tocagen is initially targeting recurrent high grade glioma (HGG) with its products, which use gene therapy to help target cancer in patients.